| Source: |
| Type: |
| Toxicity |
| Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression. TP53 is the most commonly mutated gene in human cancer. HH↑, GLI-1↑, SHH↑ P53↓ The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca. It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma. Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer. It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress. Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC. |
| 2499- | Fenb, | VitE, | Effects of fenbendazole and vitamin E succinate on the growth and survival of prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 849- | Gra, | Annona muricata silver nanoparticles exhibit strong anticancer activities against cervical and prostate adenocarcinomas through regulation of CASP9 and the CXCL1/CXCR2 genes axis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | PNT1A | - | in-vitro, | NA, | HeLa |
| 2064- | PB, | Rad, | Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 68- | QC, | BaP, | Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PrEC |
| 73- | QC, | The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90 |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 74- | QC, | EGCG, | Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer |
| - | Human, | Pca, | NA |
| 2446- | SFN, | CAP, | The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor |
| - | in-vitro, | Pca, | LNCaP |
| 1481- | SFN, | docx, | Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:22 Cells:% prod#:% Target#:1025 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid